What if weight loss
was never about
willpower?
For most of medical history, hunger was framed as a moral failing — willpower applied to a stubborn body.
Lose up to 22.5% of body weight in 72 weeks.*
*SURMOUNT-1 trial, tirzepatide 15 mg, NEJM 2022. NDP supplies the research-grade compounds.
Your body wasn't
broken.
It was waiting.
For most of medical history, hunger was framed as a moral failing. Push back from the table. Walk it off. The advice was the same for fifty years and the science behind it — was wrong.
The body had been making GLP-1 all along. A class of peptides quietly orchestrating the conversation between gut and brain about appetite, satiety, and glucose. When research learned to read that signal, the published findings reshaped endocrinology in real time: a 14.9% mean body-weight reduction in the STEP 1 trial, 22.5% in SURMOUNT-1. Outcomes no behavioural intervention has ever matched, observed across more than 21,000 patients.
NDP exists for the labs continuing that work. We make the peptides. The science writes the rest.
What the body has been quietly doing all along.
Tirzepatide,
5 mg.
The dual GIP/GLP-1 receptor agonist that posted a 22.5% mean body-weight reduction in SURMOUNT-1 — published in NEJM in 2022 and rewriting the textbook ever since. Over 400 peer-reviewed papers in three years. We make ours to ≥99.7% verified purity, lyophilised as a free-flowing powder, with a batch CoA available on request.
Process, not theatre.
Asked often.
What does "research use only" actually mean?
Our compounds are sold and supplied for laboratory and academic research. Not for human or veterinary use. Buyers confirm RUO status at checkout.
What does the research actually show about weight?
In the major published trials, GLP-1 receptor agonists have produced mean body-weight reductions far beyond what behavioural intervention alone has ever achieved — 14.9% in STEP 1 (semaglutide, NEJM 2021) and 22.5% in SURMOUNT-1 (tirzepatide, NEJM 2022). Combined enrolment across the landmark trials exceeds 21,000 patients. NDP makes the research-grade compounds for the labs continuing that work.
Do I get a Certificate of Analysis?
Yes — on request. Email us with your lot number and we'll send the Certificate of Analysis covering batch, date, HPLC purity, mass-spec confirmation, and endotoxin reading. Historical CoAs by lot number are available the same way.
How are these different from a prescription?
Pharmacy-dispensed semaglutide is the same molecule but compounded for human therapeutic use, supplied with a prescription, dosing protocol, and clinical oversight. NDP supplies research-grade compounds, sold to labs and researchers, with a Certificate of Analysis instead of a prescription. The chemistry overlaps; the use case and supply chain do not.
Storage and stability?
Sealed vials store at 2–8°C for up to 24 months. Once reconstituted, store at 2–8°C and use within the period stated on your CoA. Avoid repeated freeze-thaw cycles.